Cargando…

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study

To assess the efficacy of the combination of long-acting release (LAR) octreotide and tamoxifen (TMX) for the treatment of advanced hepatocellular carcinoma (HCC). A total of 109 patients with advanced HCC were randomised to receive octreotide LAR combined with TMX (n=56) (experimental treatment gro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verset, G, Verslype, C, Reynaert, H, Borbath, I, Langlet, P, Vandebroek, A, Peeters, M, Houbiers, G, Francque, S, Arvanitakis, M, Van Laethem, J-L
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360361/ https://www.ncbi.nlm.nih.gov/pubmed/17687341 http://dx.doi.org/10.1038/sj.bjc.6603901

Ejemplares similares

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study
por: Hendlisz, Alain, et al.
Publicado: (2013)

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors
por: Cheng, Yue, et al.
Publicado: (2023)

Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study
por: Hendlisz, Alain, et al.
Publicado: (2015)

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
por: Mercado, Moises, et al.
Publicado: (2007)

Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic review
por: Deng, Chao, et al.
Publicado: (2017)

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018)

Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study
por: Zhao, Zhe, et al.
Publicado: (2022)

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
por: Yau, Hanford, et al.
Publicado: (2017)

Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
por: Lindemann, Kristina, et al.
Publicado: (2017)

Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study
por: von Arx, Claudia, et al.
Publicado: (2020)

Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension
por: Cui, Pei-Jing, et al.
Publicado: (2017)

Preparation of long-acting microspheres loaded with octreotide for the treatment of portal hypertensive
por: Han, Bing, et al.
Publicado: (2021)

Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors
por: Al-Efraij, Khalid, et al.
Publicado: (2015)

Pharmacokinetic and technical comparison of Sandostatin(® )LAR(® )and other formulations of long-acting octreotide
por: Petersen, Holger, et al.
Publicado: (2011)

Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study
por: Li, Jie, et al.
Publicado: (2016)

Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands
por: Hagendijk, Marije E., et al.
Publicado: (2021)

Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer
por: Roeyen, G., et al.
Publicado: (2022)

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer
por: Kojima, Nobue, et al.
Publicado: (2018)

Tamoxifen Acts as a Parietal Cell Protonophore
por: Manning, E.H., et al.
Publicado: (2020)

Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO)
por: Adelman, Daphne, et al.
Publicado: (2020)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
por: Tiberg, Fredrik, et al.
Publicado: (2015)

Octreotide and hepatocellular carcinoma
por: Farinati, F, et al.
Publicado: (2007)

Successful use of long acting octreotide in two cases with Beckwith-Wiedemann syndrome and severe hypoglycemia
por: Al-Zubeidi, Hiba, et al.
Publicado: (2014)

Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment
por: LIU, YAO, et al.
Publicado: (2013)

Octreotide Uptake in Parathyroid Adenoma
por: Karaçavuş, Seyhan, et al.
Publicado: (2012)

Somatostatin receptor expression, tumour response and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide
por: Cebon, J, et al.
Publicado: (2007)

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
por: Wang, Yuhong, et al.
Publicado: (2017)

MON-LB47 An International Simulated Use Study (PRESTO) to Evaluate Nurse Preferences Between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe
por: Adelman, Daphne T, et al.
Publicado: (2020)

Citalopram/octreotide: Carcinoid heart disease, unmasking of carcinoid syndrome and development of octreotide resistance: case report
Publicado: (2021)

Mid-gut exploration: video-capsule endoscopy cannot always determine the insertion route of device-assisted enteroscopy
por: Fernandez Y Viesca, Michael, et al.
Publicado: (2022)

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis
por: Strosberg, Jonathan R, et al.
Publicado: (2015)

Therapeutic Applications of Octreotide in Pediatric Patients
por: Al-Hussaini, Abdulrahman, et al.
Publicado: (2012)

The impact of octreotide in experimental proliferative vitreoretinopathy
por: Evren, Ozge, et al.
Publicado: (2013)

Visualization of Gallbladder with In-111 Octreotide Scan
por: Özülker, Filiz, et al.
Publicado: (2015)

Octreotide Conjugates for Tumor Targeting and Imaging
por: Figueras, Eduard, et al.
Publicado: (2019)

Octreotide-Resistant Acromegaly: Challenges and Solutions
por: Corica, Giuliana, et al.
Publicado: (2020)

Octreotide Infusion for the Treatment of Congenital Chylothorax
por: Kobeisy, Sumayyah Ahmed Nezar, et al.
Publicado: (2020)

Role of Octreotide in Sulfonylurea-Induced Hypoglycemia
por: Zafar, Sheema, et al.
Publicado: (2021)

Role of octreotide in small bowel bleeding
por: Khedr, Anwar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sjjorot3e1877a0ls8468g9mro